secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001437749-24-034910
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax Q3 net loss $5.8M ($0.91/share); BARDA NextGen trial on track; special meeting adjourned
--------------------------------------------------------------------------------

- Net loss $5.8M for Q3 2024 ($0.91/share) vs $8.4M ($4.75/share) in Q3 2023; nine-month net loss $16.7M ($4.52/share).
- Revenue of $2.8M from BARDA/RRPV Project NextGen award (no revenue in prior year period).
- Cash $8.6M at Sep 30, 2024, vs $6.5M at Dec 31, 2023.
- BARDA Phase 2b trial of GEO-CM04S1 (10,000 patients) preparing for activation; sites confirmed.
- Special Meeting adjourned without business due to lack of quorum (30.4% proxy turnout); reconvened Dec 18, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774924034910/0001437749-24-034910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774924034910/govx20241113_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-034910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer